Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir.
about
Clinical effectiveness of dolutegravir in the treatment of HIV/AIDSDolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIVEffects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir.Once-Daily, Single-Tablet Regimens For the Treatment of HIV-1 InfectionThe role of dolutegravir in the management of HIV infectionPharmacokinetic profile of raltegravir, elvitegravir and dolutegravir in plasma and mucosal secretions in rhesus macaquesPharmacokinetics of dolutegravir when administered with mineral supplements in healthy adult subjects.Dolutegravir Has No Effect on the Pharmacokinetics of Oral Contraceptives With Norgestimate and Ethinyl Estradiol.Potential benefit of dolutegravir once daily: efficacy and safety.Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor dolutegravir in humansDolutegravir pharmacokinetics in the genital tract and colorectum of HIV-negative men after single and multiple dosing.Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir.Dolutegravir.Pharmacology of HIV integrase inhibitors.Dolutegravir: first global approval.Dolutegravir, a second-generation integrase inhibitor for the treatment of HIV-1 infection.Dolutegravir: a new integrase strand transfer inhibitor for the treatment of HIV.Dolutegravir: an exciting new kid on the block.Dolutegravir for the treatment of adult patients with HIV-1 infection.Dolutegravir: a next-generation integrase inhibitor for treatment of HIV infection.Dolutegravir: a review of its use in the management of HIV-1 infection in adolescents and adults.Evaluation of dolutegravir safety for the treatment of HIV-1.Clinical pharmacokinetics and pharmacodynamics of dolutegravir used as a single tablet regimen for the treatment of HIV-1 infection.Use of Integrase Inhibitors in HIV-Infected Children and Adolescents.Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors.Abacavir + dolutegravir + lamivudine for the treatment of HIV.Switching from a ritonavir-boosted PI to dolutegravir as an alternative strategy in virologically suppressed HIV-infected individuals.A Two-Way Steady-State Pharmacokinetic Interaction Study of Doravirine (MK-1439) and Dolutegravir.A review of drug-drug interactions in older HIV-infected patients.Divalent metals and pH alter raltegravir disposition in vitro.Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV.Dolutegravir: An Integrase Strand Transfer Inhibitor for the Treatment of Human Immunodeficiency Virus 1 in Adults.Dolutegravir: a new option for HIV treatment
P2860
Q26778450-17EBA867-DA93-40BB-8616-2F0C354940C1Q26799712-13314B9D-FAA7-41E9-9781-59C55C1125EEQ34151623-462A8887-38CD-492E-98E1-3C0864385F6CQ34976284-EACC0B76-3314-4A8B-83CA-F32C63C91E94Q35121450-A6276E91-A0DE-4B39-A964-790977747C3FQ35432739-CFE5C296-1B2F-4E97-B3C8-4AD034451B8DQ35532581-8C75E2FD-9E32-4D0C-AFA9-E955EA6FC4B1Q35756542-1DC63D4C-7979-40BC-97A5-88FF857D34A6Q36603416-EECFA12A-A948-42E3-B194-26A4C3090D3CQ37036624-DC919251-74D0-4EE2-9580-90A9131F4C31Q37246359-81FEA88C-772F-4D2F-8BFF-056FD8E707EFQ37248656-902BFADA-F248-4F13-835D-B948CAD9DB7DQ37614157-0E0CBB19-20F2-455D-B054-0F53E37C2695Q38025835-FF39017D-55A0-40EC-8DAA-75B9835ED3DAQ38139885-507F2BD0-59B3-4475-B888-A96BD2A6918AQ38164678-B8CA0891-3E16-441C-A905-DC145D1184E6Q38172029-E2B4C6F3-8CCA-4E3E-A992-3E44A9477CA8Q38180458-76DD864A-4BA5-44D3-8C19-C9A1D6351ADDQ38201520-67D68E98-1A4C-4F63-A902-83A3E502BF41Q38203844-19EDEFC4-F54F-465F-8DAB-7B5FEAA67D8CQ38227491-E2578B4F-31E6-4DE6-8214-787E58DECA88Q38262935-558C2308-25E5-4565-839D-6065756F38FAQ38541809-F436FE29-C8BF-4F1E-90D0-1D4D2714AFFDQ38560855-805BAED5-9266-490D-B8CC-7916E64253A0Q38868949-48EDA548-5652-4D9D-8FD1-451D6CEF4A36Q38951349-66AC7C2B-12E9-478E-9F12-B0C265683BFAQ40401577-A0CB6879-4410-41C9-BFEB-CA65D3B7A470Q40517770-4E8FE030-8A7D-412A-AB6C-46ADBAA36DD1Q41996857-231D3EAD-06EB-4308-9DA6-93B0660E6446Q42189797-FBA8A6E1-4F9C-4143-8E47-08EFFD84103AQ47548999-CF06A4C0-88F2-4954-985D-574D1B217139Q55309394-4FC6A0B0-2428-4FFE-B8ED-69A8C544181DQ58290460-1089B7C6-6163-40EF-9008-1EDC20515ABE
P2860
Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir.
@ast
Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir.
@en
type
label
Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir.
@ast
Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir.
@en
prefLabel
Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir.
@ast
Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir.
@en
P2093
P2860
P356
P1476
Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir.
@en
P2093
Amanda Peppercorn
Julie Borland
Parul Patel
Shuguang Chen
Stephen C Piscitelli
Toshihiro Wajima
P2860
P304
P356
10.1128/AAC.05739-11
P407
P577
2011-12-19T00:00:00Z